Literature DB >> 10937467

Juvenile myasthenia: diagnosis and treatment.

B Anlar1.   

Abstract

Myasthenia in children can be juvenile (autoimmune) or congenital. Juvenile myasthenia (JM) is an autoimmune disorder characterised by fluctuating weakness and fatigue in the ocular, facial, bulbar or limb muscles. Diagnosis is confirmed by electromyography (EMG), single fibre EMG and the patient's clinical response to anticholinesterase medication. Serology is less helpful in children because acetylcholine receptor antibodies, usually positive in adults, are frequently absent in patients with prepubertal onset of the disease. Treatment methods in JM include anticholinesterase drugs, thymectomy and immunomodulatory agents. Plasmapheresis and intravenous immunoglobulin are used in myasthenic crisis. The prognosis of patients with JM is usually good, clinical remission being achieved in the majority of patients with the current treatment methods.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10937467     DOI: 10.2165/00128072-200002030-00001

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  37 in total

1.  Thymectomy in children with generalized myasthenia gravis.

Authors:  G P Ramelli; M Sturzenegger; M G Bianchetti; F Vassella
Journal:  Neuropediatrics       Date:  1997-10       Impact factor: 1.947

2.  Acetylcholine receptor antibodies and single-fiber EMG in first-degree relatives of children with myasthenia gravis.

Authors:  B Anlar; R Kuruoğlu; K Varli; Y Renda
Journal:  Neuropediatrics       Date:  1995-12       Impact factor: 1.947

3.  Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients.

Authors:  A Lindner; B Schalke; K V Toyka
Journal:  J Neurol       Date:  1997-08       Impact factor: 4.849

4.  Thymectomy in juvenile myasthenia gravis.

Authors:  C Adams; D Theodorescu; E G Murphy; B Shandling
Journal:  J Child Neurol       Date:  1990-07       Impact factor: 1.987

5.  Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis.

Authors:  P I Andrews; J M Massey; J F Howard; D B Sanders
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

6.  Myasthenia gravis in childhood.

Authors:  B Anlar; E Ozdirim; Y Renda; K Yalaz; S Aysun; M Topçu; H Topaloğlu
Journal:  Acta Paediatr       Date:  1996-07       Impact factor: 2.299

7.  The single-fiber EMG in chronic demyelinating neuropathy.

Authors:  S J Oh
Journal:  Muscle Nerve       Date:  1989-05       Impact factor: 3.217

8.  Strong association of HLA BW46 with juvenile onset myasthenia gravis in Hong Kong Chinese.

Authors:  B R Hawkins; W Y Chan-Lui; E K Choi; A Y Ho
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

9.  Myasthenia gravis in childhood and infancy. Usefulness of electrophysiologic studies.

Authors:  C Vial; N Charles; G Chauplannaz; B Bady
Journal:  Arch Neurol       Date:  1991-08

10.  Topical therapy for oropharyngeal symptoms of myasthenia gravis.

Authors:  J M Dooley; K J Goulden; J G Gatien; E J Gibson; B S Brown
Journal:  Ann Neurol       Date:  1986-02       Impact factor: 10.422

View more
  1 in total

1.  Anaesthetic considerations in paediatric myasthenia gravis.

Authors:  Oliver William Masters; Oliver N Bagshaw
Journal:  Autoimmune Dis       Date:  2011-09-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.